US

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Republic of Korea *

cdc-assay-app-note1920x640

Application Note

Optimization of complement-dependent cytotoxicity assay on OncoSignature cell lines

Screening candidate mAbs for complement-dependent cytotoxicity (CDC) activity represents a crucial step in the development pipeline of successful therapeutics.

In this application note, we present how our complement-dependent cytotoxicity (CDC) assay offering can help drug screening efforts by leveraging our semi-automated screening platform and OncoSignature™ cell panel.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

Have a sales representative contact me

First Name

Last Name

Country

Email Address

Company

Zip / Postal Code

Business Phone

Role

Products and Services of Interest

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

Download Resource

Optimization of complement-dependent cytotoxicity assay on OncoSignature cell lines

Download Application Note